1. Home
  2. Press release
Oct, 01 2019 11:46 JST

Source: Eisai

Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress


TOKYO, Oct, 01 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE- 146/Study 111 evaluating LENVIMA, an orally available kinase inhibitor discovered by Eisai , plus KEYTRUDA, Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy. The findings were presented in a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract #994O).

For the full report, visit https://www.eisai.com/news/2019/pdf/enews201977pdf.pdf.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.


Contact:
Eisai Co., Ltd. 
Media Relations 
+81-(0)3-3817-5120

Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations 
Pamela Eisele: (267) 305-3558 
Kristen Drake: (908) 334-4688
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
October 23 2019 10:13 JST
 
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
October 15 2019 20:24 JST
 
Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China
September 30 2019 11:06 JST
 
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia
September 26 2019 13:21 JST
 
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients
September 26 2019 13:08 JST
 
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress
September 24 2019 09:01 JST
 
Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan
September 20 2019 15:13 JST
 
Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India
September 20 2019 08:40 JST
 
Eisai to Present Latest Data on Lemborexant at World Sleep Congress
September 19 2019 19:06 JST
 
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019
September 18 2019 20:40 JST
 
More Press release >>

Latest Press Release


Honda Unveils the World Premiere of All-new Fit at the 46th Tokyo Motor Show 2019
Oct 23, 2019 11:29 JST

Honda to Evolve its Original High-Efficiency Electrification Technologies as "Honda e:TECHNOLOGY"
Oct 23, 2019 11:24 JST

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Oct 23, 2019 11:13 JST

Hitachi: Company Split of the Analysis Contract Service Business and the Transfer of Stock of the New Company
Oct 21, 2019 18:10 JST

Toyota Yaris WRC Set for Crucial Mixed-surface Spectacular
Oct 18, 2019 17:37 JST

Overview of Honda Exhibits at the 26th ITS World Congress 2019 in Singapore
Oct 18, 2019 15:46 JST

Hitachi Automotive Systems Starts Mass Production of High Voltage and High Output EV Inverter, the First in the World
Oct 18, 2019 15:33 JST

Hitachi Launches Dashboard for Building Owners and Managers to Check the Operation and Maintenance Status of Building Facilities, Including Elevators
Oct 18, 2019 09:03 JST

Toyota to Show Production-Ready Ultra-Compact BEV at 2019 Tokyo Motor Show "FUTURE EXPO"
Oct 17, 2019 13:48 JST

Monumental Sports & Entertainment, NEC Announce Partnership with Washington Wizards
Oct 16, 2019 17:45 JST

NEC Announces First International Partnership with Professional Basketball Player Rui Hachimura
Oct 16, 2019 17:33 JST

Hitachi and Frasers Property Sign S$100 Million MOU to Drive Digital Transformation in the Real Estate Industry in Asia Pacific
Oct 16, 2019 16:02 JST

Toyota's New Model Yaris Makes World Premiere
Oct 16, 2019 15:32 JST

Ministry of Movement and NEC to Collaborate on Future of Urban Mobility
Oct 16, 2019 15:04 JST

Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
Oct 15, 2019 21:24 JST

Fujitsu's Gymnastics Judging Support System Wins the "Minister of Internal Affairs and Communications Award" at CEATEC 2019
Oct 15, 2019 16:25 JST

Fujitsu Develops AI based Facial Expression Recognition Technology to Accurately Detect Subtle Changes in Expression
Oct 15, 2019 16:09 JST

Toyota Rolls Out New Compact Convertible Sports Car "Copen GR SPORT" in Japan
Oct 15, 2019 14:09 JST

Mazda Publishes Mazda Sustainability Report 2019 and Annual Report 2019
Oct 15, 2019 13:27 JST

Mazda Included in Dow Jones Sustainability Asia Pacific Index for Third Year Running
Oct 15, 2019 13:16 JST
 More Latest Release >>